

## References

### I-225

1. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 06/2020.
2. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf.
3. Micromedex DrugDex Compendium®. 2023 Pertuzumab/Trastuzumab/Hyaluronidase-zzxf.
4. National Comprehensive Cancer Network (NCCN). Pertuzumab, trastuzumab, and hyaluronidase-zzxf. NCCN Drugs and Biologics Compendium®. 2022.
5. Woodward N, De Boer RH, Redfern A, et al. Results from the first multicenter, open-label, phase iiib study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). *Clinical Breast Cancer*. 2019;19(3):216-224.
6. Kirschbrown WP, Kågedal M, Wang B, et al. Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: Results from the phase Ib dose-finding study. *J Clin Pharmacol*. 2019;59(5):702-716.
7. Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 3, 2020.
8. Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. *Lancet Oncol*. 2021;22(1):85-97.